Navigation Links
Revised: Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
Date:3/24/2008

GRAND RAPIDS, Mich., March 24 /PRNewswire/ -- What happens when leading biochemists get together to challenge conventional pharmaceutical theories? Often, incredible new drug therapies are born. Recently, this same scenario began when two former major pharma scientists challenged the concept behind the leading treatments for type 2 diabetes, a disease that impacts millions of Americans. They saw the side effects caused by the current therapy like edema and weight gain, and went to work on a hypothesis that the current receptor was leading to these side effects associated with PPAR-based therapies.

As non-conventional as the theory was, it's working. Drs. Jerry Colca and Rolf Kletzien, co-founders of Kalamazoo, Michigan-based Metabolic Solutions Development Company (MSDC), have completed Phase I clinical studies and just received second phase funding from a Michigan-based science fund. They have applied for an FDA fast-track review of their work.

"We are pleased that our lead compound performed so well in Phase I studies," said Colca, MSDC's chief scientific officer. "Pre-clinical studies suggest that this compound can deliver significant pharmacological benefit without the complications inherent in current PPAR-based therapies."


'/>"/>
SOURCE Metabolic Solutions Development Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
2. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
3. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
4. Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
5. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
6. Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of sub-acute ... of a disaster drill on October 3rd. , Apple Rehab participated with the Shelton ... well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The LTC-MAP ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
Breaking Medicine News(10 mins):